Company: FTII
Filing Date: 2025-04-09
Form Type: 10-K
Source: 0001641172-25-003384
Chunk: 521

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-04-09
Form: 10-K
Item: Item 1
Chunk 521
---
ger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary
of the Company (“Merger Sub”), and Bradford A. Zakes, solely in the capacity as seller representative. Longevity is a biopharmaceutical
company focused on the advancement of impactful new technologies and services across therapeutics, monitoring and digital health that
address diseases associated with aging and were formed to pursue acquisitions of target companies in the medical technology and biomedical
life sciences industries.

The
Merger Agreement provides that the parties thereto will enter into a business combination transaction (the “Longevity Business
Combination” and together with the other transactions contemplated by the Merger Agreement, the “Transactions”), pursuant
to which, among other things, (i) Longevity will consummate Target Acquisitions (as defined therein) upon the terms and subject to conditions
set forth therein and pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation
of the Target Acquisitions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving
company of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of the Company. At the closing of the Transactions
(the “Closing”), the Company is expected to change its name to “Longevity Biomedical, Inc.” and the Company’s
common stock is expected to list on the Nasdaq Stock Market under the ticker symbol “LBIO.”

The
consummation of the proposed Longevity Business Combination is subject to certain conditions as further described in the Merger Agreement.

In
connection with the execution of the Merger Agreement, the sole stockholder of Longevity (the “Voting Stockholder”) has entered
into a Voting and Support Agreement (the “Longevity Support Agreement”), pursuant to which the Voting Stockholder has agreed
to, among other things, (i) vote in favor of the Merger Agreement and the transactions contemplated thereby and (ii) be bound by certain
other covenants and agreements related to the Transactions. The Voting Stockholder holds sufficient shares of Longevity to cause the
approval of the Transactions on behalf of Longevity.

In
connection with the execution of the Merger Agreement, the Company, the Sponsor has entered into a Voting and Support Agreement (the
“Sponsor Support Agreement”). The Sponsor Support Agreement provides that the Sponsor agrees (i) to vote in favor of the
proposed transactions contemplated by the Merger Agreement,